A Phase 2, Double-Blind, Randomized Safety And Efficacy Study Of Glasdegib (PF-04449913) Versus Placebo In Patients With Myelofibrosis Previously Treated With Ruxolitinib

Trial Profile

A Phase 2, Double-Blind, Randomized Safety And Efficacy Study Of Glasdegib (PF-04449913) Versus Placebo In Patients With Myelofibrosis Previously Treated With Ruxolitinib

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 23 Aug 2017

At a glance

  • Drugs Glasdegib (Primary)
  • Indications Myelofibrosis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 06 Jun 2017 Results of the single-arm lead-in cohort (n=21) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 06 Jun 2017 Planned End Date changed from 25 Oct 2017 to 1 Dec 2017.
    • 13 May 2017 This trial has been completed in Austria.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top